How CDMOs can help reduce the risk of counterfeit medicines entering the supply chain

There is an ongoing risk of counterfeit medicines entering the legal supply chain and the pharmaceutical industry continues to take the necessary steps to tackle this problem. Various serialisation legislation has been introduced in key markets to improve the traceability of all medicines. 

When serialisation regulations were first introduced, Recipharm assembled a dedicated taskforce to clearly identify the compliance requirements globally.

It is of course crucial that companies stay on top of these evolving regulations. When it comes to the non-regulated online supply chain, there is still a long way to go and therefore it is likely that the industry will see more regulations put in place to bring governance in line with the offline supply of medicines.

When serialisation regulations were first introduced, Recipharm assembled a dedicated taskforce to clearly identify the compliance requirements globally and determine the appropriate measures to ensure minimal impact on our customers and their supply chains. 

In an article with the Small Molecule Manufacturer, Staffan Widengren, Director Corporate Projects at Recipharm, discusses the current state of play and the challenges that CDMOs continue to face when it comes to preventing counterfeit medicines entering the legal supply chain.

You can click here to read the full article.